<DOC>
	<DOC>NCT02707523</DOC>
	<brief_summary>The proposed study will be a randomized, double masked, placebo-controlled pilot trial of azithromycin treatment in children with RSV-induced respiratory failure.</brief_summary>
	<brief_title>Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced (Respiratory Syncytial Virus - Induced) Respiratory Failure In Children</brief_title>
	<detailed_description>Study participants will be enrolled from the Pediatric Intensive Care Unit (PICU) at Children's of Alabama. Samples collected will be analyzed in the PI's lab at the University of Alabama at Birmingham. Drug pharmacokinetics will be performed at the Pharmaceutical Sciences Research Institute of Samford University, Birmingham, AL.</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>Admission to the PICU with RSV infection and mechanical ventilation Randomization and drug/placebo initiation within 48 hours of mechanical ventilation Age less than 2 years Azithromycin use within 7 days of PICU admission Contraindication to azithromycin use including: Patients with electrocardiogram QT interval corrected for heart rate (Qtc) â‰¥ 450 ms Patients with significant hepatic impairment (direct bilirubin &gt;1.5 mg/dL) Known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug Cardiac arrhythmia History of pyloric stenosis Immunocompromised children (any cause) Current use of any medication known to cause QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RSV</keyword>
	<keyword>respiratory support</keyword>
	<keyword>RSV induced respiratory failure</keyword>
</DOC>